Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences Inc. (DTIL) filed a Current Report on Form 8-K on November 3, 2025. The filing announces the financial results for the quarter ended September 30, 2025. The full details of these results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not included in the body of this 8-K document.
Material Changes
No material changes versus the prior comparable period are described in the text of this filing. The document serves solely as a notification that results have been issued.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. Such information is expected to be found in the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 revenue and net loss figures.
- Verify cash position and burn rate details in the full press release.
- Check for any updated guidance or clinical trial milestones mentioned in the press release.
- Confirm the filing date of November 3, 2025, aligns with the company's reporting calendar.